ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 094,97
-0,09%
Dow Jones
39 069,59
0,01%
DAX
18 693,37
0,04%
Brent Oil
81,965
0,00%
Bitcoin
69 255,84
-0,02%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. NeuroSense Therapeutics Ltd (NRSN)

  7. NeuroSense Therapeutics Ltd (NRSN) Actualités

NRSN

NeuroSense Therapeutics (NRSN)

NeuroSense Therapeutics Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NRSN
DateHeureSourceTitreSymboleSociété
20/05/202415h00PR Newswire (US)NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development SummitNASDAQ:NRSNNeuroSense Therapeutics Ltd
14/05/202415h05PR Newswire (US)NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine LearningNASDAQ:NRSNNeuroSense Therapeutics Ltd
07/05/202414h45PR Newswire (US)NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS PatientsNASDAQ:NRSNNeuroSense Therapeutics Ltd
02/05/202415h19PR Newswire (US)NeuroSense Announces First Quarter 2024 Business UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
22/04/202414h30PR Newswire (US)NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's DiseaseNASDAQ:NRSNNeuroSense Therapeutics Ltd
18/04/202414h30PR Newswire (US)NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual MeetingNASDAQ:NRSNNeuroSense Therapeutics Ltd
12/04/202414h30PR Newswire (US)NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024NASDAQ:NRSNNeuroSense Therapeutics Ltd
11/04/202401h16PR Newswire (US)NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private PlacementNASDAQ:NRSNNeuroSense Therapeutics Ltd
09/04/202414h30PR Newswire (US)NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and DiagnosticsNASDAQ:NRSNNeuroSense Therapeutics Ltd
05/04/202415h29PR Newswire (US)NeuroSense Announces Year End 2023 Financial Results and Provides Business UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
22/02/202414h25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
21/02/202414h30PR Newswire (US)NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialNASDAQ:NRSNNeuroSense Therapeutics Ltd
13/02/202419h20Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NRSNNeuroSense Therapeutics Ltd
07/02/202415h27PR Newswire (US)NeuroSense Regains Compliance with NASDAQ Minimum Bid Price RuleNASDAQ:NRSNNeuroSense Therapeutics Ltd
09/01/202414h45PR Newswire (US)NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 CatalystsNASDAQ:NRSNNeuroSense Therapeutics Ltd
27/12/202323h03Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NRSNNeuroSense Therapeutics Ltd
27/12/202323h00PR Newswire (US)NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementNASDAQ:NRSNNeuroSense Therapeutics Ltd
14/12/202315h24PR Newswire (US)NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS TrialNASDAQ:NRSNNeuroSense Therapeutics Ltd
05/12/202314h00PR Newswire (US)NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy EndpointsNASDAQ:NRSNNeuroSense Therapeutics Ltd
05/12/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NRSNNeuroSense Therapeutics Ltd
04/12/202322h01PR Newswire (US)NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023NASDAQ:NRSNNeuroSense Therapeutics Ltd
04/12/202312h17Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NRSNNeuroSense Therapeutics Ltd
28/11/202314h45PR Newswire (US)NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
13/11/202315h20PR Newswire (US)NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial ReadinessNASDAQ:NRSNNeuroSense Therapeutics Ltd
09/11/202315h00PR Newswire (US)NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS ConferencesNASDAQ:NRSNNeuroSense Therapeutics Ltd
06/11/202314h30PR Newswire (US)NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023NASDAQ:NRSNNeuroSense Therapeutics Ltd
01/11/202314h00PR Newswire (US)NeuroSense Therapeutics to Participate in BIO-Europe FallNASDAQ:NRSNNeuroSense Therapeutics Ltd
17/10/202314h30PR Newswire (US)NeuroSense CEO Provides Q3 2023 UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
04/10/202315h10PR Newswire (US)NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC ModelNASDAQ:NRSNNeuroSense Therapeutics Ltd
20/09/202315h05PR Newswire (US)European Medicines Agency Grants NeuroSense SME StatusNASDAQ:NRSNNeuroSense Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:NRSN

Dernières Valeurs Consultées

EU
MC
Lvmh Moet Hennessy Louis...
EU
EN
Bouygues
EU
VIV
Vivendi
NYSE
MCD
McDonalds
EU
RI
Pernod Ricard
EU
AF
Air FranceKLM
USI
USTECH100
US Tech 100
NYSE
MRK
Merck
SPI
SP500
S&P 500
EU
BEL20
Bel 20
EU
SGO
Cie de SaintGobain
NYSE
JPM
JP Morgan Chase
EU
PX4
SBF 120
NYSE
NKE
Nike
EU
BNP
BNP Paribas
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés